Please Wait.....
Report
Hepatitis B Vaccine Market Report and Forecast 2024-2032
Market Report I 2023-10-01 I 160 Pages I EMR Inc.
Hepatitis B Vaccine Market Report and Forecast 2024-2032
Hepatitis B Vaccine Market Outlook
The hepatitis b vaccine market size was valued at USD 4.8 billion in 2023, driven by a combination of factors. The market size is anticipated to grow at a CAGR of 4.8% during the forecast period of 2024-2032 to achieve a value of USD 7.3 billion by 2032.
Hepatitis B Vaccine: Introduction
The Hepatitis B vaccine is a vital immunization tool designed to prevent Hepatitis B; a potentially life-threatening liver infection caused by the Hepatitis B virus (HBV). This vaccine provides immunity by introducing a small part of the virus's outer surface into the body, prompting the immune system to develop antibodies without causing the disease itself. Hepatitis B can lead to severe health issues, including cirrhosis, liver cancer, and even death.
The vaccine's introduction has been a major medical breakthrough, significantly reducing the number of new infections and providing protection for a lifetime when administered in a full series. It is typically given in multiple doses, starting from birth in many countries, and is considered one of the most effective ways to prevent the spread of this contagious disease. The widespread adoption of the Hepatitis B vaccine has played a pivotal role in the global fight against liver-related illnesses and has been instrumental in safeguarding countless individuals from the complications of HBV.
Key Trends in the Hepatitis B Vaccine Market
The Hepatitis B vaccine market has experienced several notable trends driven by various factors. Firstly, there's an increased emphasis on government-led immunization programs, especially in countries with a high prevalence of Hepatitis B infections. Many governments have incorporated Hepatitis B vaccination into their national immunization schedules, starting from birth or early childhood, to ensure widespread coverage. Another trend is the ongoing research and development aimed at enhancing vaccine efficacy and duration of immunity. This includes efforts to create combination vaccines that can protect against multiple diseases with fewer shots. The rise in travel and migration has also spurred demand for the vaccine, as individuals move to or visit areas endemic with the virus.
Moreover, public awareness campaigns have gained momentum, highlighting the importance of vaccination and its role in preventing potential complications of Hepatitis B like liver cirrhosis or cancer. However, the market faces challenges too, including supply constraints and the need for cold storage, which can limit vaccine accessibility in certain regions. In essence, the Hepatitis B vaccine market is shaped by a blend of public health initiatives, scientific advancements, and socio-economic factors, all converging to combat a major liver-related threat.
Hepatitis B Vaccine Market Segmentation
Market Breakup by Type
- Single Antigen
- Combination
Market Breakup by Age
- Pediatrics
- Adults
Market Breakup by End User
- Hospitals
- Clinics
- Vaccination Centres
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
o Germany
o France
o Italy
o Spain
o United Kingdom
- Japan
Hepatitis B Vaccine Market Overview
The Hepatitis B vaccine market is a significant segment within the broader pharmaceutical landscape, underscored by the critical need to prevent Hepatitis B-a serious liver infection that can lead to severe complications like cirrhosis and liver cancer. The market's growth has been driven by a combination of factors. Government initiatives and health organizations have stressed the importance of immunization, leading to the inclusion of the Hepatitis B vaccine in national immunization programs across many countries. This widespread adoption, especially in regions with a high prevalence of the disease, has led to increased vaccine demand. Additionally, the market has benefited from consistent R&D efforts, leading to innovations like combination vaccines and enhanced formulations.
Challenges such as vaccine accessibility in remote regions, pricing issues in some markets, and occasional supply chain bottlenecks have occasionally hindered the market's growth. However, collaborations between governments, international organizations, and vaccine manufacturers aim to address these challenges and ensure broader vaccine distribution. In essence, the Hepatitis B vaccine market is characterized by its central role in public health efforts, continuous innovation, and the collective drive to achieve worldwide immunization against this dangerous disease.
Hepatitis B Vaccine Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Merck & Co.,Inc.
- Sanofi S.A.
- Dynavax Technologies Corporation
- GlaxoSmithKline plc.
- Pancea Biotech Ltd
- Beijing Tiantan Biological Products Co., Ltd.
- VBI Vaccines Inc.
- Emmy Vaccine Co.,Ltd.
- Beijing Minhai Biological Technology Co., Ltd.
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Hepatitis B Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Hepatitis B Disease Epidemiology Analysis - 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Hepatitis B Disease Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Hepatitis B Disease Epidemiology Forecast (2017-2032)
5.3.1 Germany Hepatitis B Disease Epidemiology Forecast (2017-2032)
5.3.2 France Hepatitis B Disease Epidemiology Forecast (2017-2032)
5.3.3 Italy Hepatitis B Disease Epidemiology Forecast (2017-2032)
5.3.4 Spain Hepatitis B Disease Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Hepatitis B Disease Epidemiology Forecast (2017-2032)
5.4 Japan Hepatitis B Disease Epidemiology Forecast (2017-2032)
6 Hepatitis B Vaccine Market Overview - 7MM
6.1 Hepatitis B Vaccine Market Historical Value (2017-2023)
6.2 Hepatitis B Vaccine Market Forecast Value (2024-2032)
7 Hepatitis B Vaccine Market Landscape - 7MM
7.1 Hepatitis B Vaccine: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Hepatitis B Vaccine: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Treatment Type
7.2.3 Analysis by Diagnosis Method
8 Hepatitis B Vaccine Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Hepatitis B Vaccine Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter's Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Hepatitis B Vaccine Market Segmentation - 7MM
11.1 Hepatitis B Vaccine Market by Type
11.1.1 Market Overview
11.1.2 Single Antigen
11.1.3 Combination
11.2 Hepatitis B Vaccine Market by Age
11.2.1 Market Overview
11.2.2 Pediatrics
11.2.3 Adults
11.3 Hepatitis B Vaccine Market by End User
11.3.1 Market Overview
11.3.2 Hospitals
11.3.3 Clinics
11.3.4 Vaccination Centres
11.3.5 Others
11.4 Hepatitis B Vaccine Market by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
12 United States Hepatitis B Vaccine Market
12.1 Hepatitis B Vaccine Market Historical Value (2017-2023)
12.2 Hepatitis B Vaccine Market Forecast Value (2024-2032)
12.3 Hepatitis B Vaccine Market by Type
12.4 Hepatitis B Vaccine Market by Treatment Type
13 EU-4 and United Kingdom Hepatitis B Vaccine Market
13.1 Hepatitis B Vaccine Market Historical Value (2017-2023)
13.2 Hepatitis B Vaccine Market Forecast Value (2024-2032)
13.3 Germany Hepatitis B Vaccine Market Overview
13.3.1 Hepatitis B Vaccine Market by Type
13.3.2 Hepatitis B Vaccine Market by Treatment Type
13.4 France Hepatitis B Vaccine Market Overview
13.4.1 Hepatitis B Vaccine Market by Type
13.4.2 Hepatitis B Vaccine Market by Treatment Type
13.5 Italy Hepatitis B Vaccine Market Overview
13.5.1 Hepatitis B Vaccine Market by Type
13.5.2 Hepatitis B Vaccine Market by Treatment Type
13.6 Spain Hepatitis B Vaccine Market Overview
13.6.1 Hepatitis B Vaccine Market by Type
13.6.2 Hepatitis B Vaccine Market by Treatment Type
13.7 United Kingdom Hepatitis B Vaccine Market Overview
13.7.1 Hepatitis B Vaccine Market by Type
13.7.2 Hepatitis B Vaccine Market by Treatment Type
14 Japan Hepatitis B Vaccine Market
14.1 Hepatitis B Vaccine Market Historical Value (2017-2023)
14.2 Hepatitis B Vaccine Market Forecast Value (2024-2032)
14.3 Hepatitis B Vaccine Market by Type
14.4 Hepatitis B Vaccine Market by Treatment Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 INDIA CDSCO
15.1.4 JAPAN PMDA
15.1.5 Others
16 Clinical Trials Analysis
16.1 Analysis by Trial Registration Year
16.2 Analysis by Trial Status
16.3 Analysis by Trial Phase
16.4 Analysis by Therapeutic Area
16.5 Analysis by Geography
17 Funding and Investment Analysis
17.1 Analysis by Funding Instances
17.2 Analysis by Type of Funding
17.3 Analysis by Funding Amount
17.4 Analysis by Leading Players
17.5 Analysis by Leading Investors
17.6 Analysis by Geography
18 Partnership and Collaborations Analysis
18.1 Analysis by Partnership Instances
18.2 Analysis by Type of Partnership
18.3 Analysis by Leading Players
18.4 Analysis by Geography
19 Supplier Landscape
19.1 Merck & Co.,Inc.
19.1.1 Financial Analysis
19.1.2 Product Portfolio
19.1.3 Demographic Reach and Achievements
19.1.4 Mergers and Acquisitions
19.1.5 Certifications
19.2 Sanofi S.A.
19.2.1 Financial Analysis
19.2.2 Product Portfolio
19.2.3 Demographic Reach and Achievements
19.2.4 Mergers and Acquisitions
19.2.5 Certifications
19.3 Dynavax Technologies Corporation
19.3.1 Financial Analysis
19.3.2 Product Portfolio
19.3.3 Demographic Reach and Achievements
19.3.4 Mergers and Acquisitions
19.3.5 Certifications
19.4 GlaxoSmithKline plc.
19.4.1 Financial Analysis
19.4.2 Product Portfolio
19.4.3 Demographic Reach and Achievements
19.4.4 Mergers and Acquisitions
19.4.5 Certifications
19.5 Pancea Biotech Ltd
19.5.1 Financial Analysis
19.5.2 Product Portfolio
19.5.3 Demographic Reach and Achievements
19.5.4 Mergers and Acquisitions
19.5.5 Certifications
19.6 Beijing Tiantan Biological Products Co., Ltd.
19.6.1 Financial Analysis
19.6.2 Product Portfolio
19.6.3 Demographic Reach and Achievements
19.6.4 Mergers and Acquisitions
19.6.5 Certifications
19.7 VBI Vaccines Inc.
19.7.1 Financial Analysis
19.7.2 Product Portfolio
19.7.3 Demographic Reach and Achievements
19.7.4 Mergers and Acquisitions
19.7.5 Certifications
19.8 Emmy Vaccine Co.,Ltd.
19.8.1 Financial Analysis
19.8.2 Product Portfolio
19.8.3 Demographic Reach and Achievements
19.8.4 Mergers and Acquisitions
19.8.5 Certifications
19.9 Beijing Minhai Biological Technology Co., Ltd.
19.9.1 Financial Analysis
19.9.2 Product Portfolio
19.9.3 Demographic Reach and Achievements
19.9.4 Mergers and Acquisitions
19.9.5 Certifications
20 Hepatitis B Vaccine - Distribution Model (Additional Insight)
20.1 Overview
20.2 Potential Distributors
20.3 Key Parameters for Distribution Partner Assessment
21 Key Opinion Leaders (KOL) Insights (Additional Insight)
22 Company Competitiveness Analysis (Additional Insight)
22.1 Very Small Companies
22.2 Small Companies
22.3 Mid-Sized Companies
22.4 Large Companies
22.5 Very Large Companies
23 Payment Methods (Additional Insight)
23.1 Government Funded
23.2 Private Insurance
23.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security